City Therapeutics, Inc. Common Stock Market Cap ($911.01 Million)
Market Cap & Net Worth: City Therapeutics, Inc. Common Stock (CTY)
City Therapeutics, Inc. Common Stock market cap. City Therapeutics, Inc. Common Stock (NASDAQ:CTY) has a market capitalization of $911.01 Million ($911.01 Million) as of November 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9050 globally and #2589 in its home market, demonstrating a 6.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying City Therapeutics, Inc. Common Stock's stock price $18.10 by its total outstanding shares 50332279 (50.33 Million). Also see how efficiently does City Therapeutics, Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
City Therapeutics, Inc. Common Stock Market Cap History (2026–2026)
City Therapeutics, Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $911.01 Million to $911.01 Million (0.00% CAGR). Check City Therapeutics, Inc. Common Stock (CTY) share price today for real-time trading data and today's change.
City Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how City Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore City Therapeutics, Inc. Common Stock annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTY by Market Capitalization
Companies near City Therapeutics, Inc. Common Stock in the global market cap rankings as of November 16, 2026. Also see City Therapeutics, Inc. Common Stock total assets for a full breakdown of the balance sheet.
Key companies related to City Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #286 globally with a market cap of $93.55 Billion USD.
- Moderna Inc (NASDAQ:MRNA): Ranked #304 globally with a market cap of $90.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $69.66 Billion USD ( AU$98.45 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $538.60 |
| #286 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $93.55 Billion | $955.47 |
| #304 | Moderna Inc | NASDAQ:MRNA | $90.38 Billion | $223.37 |
| #412 | CSL Ltd | AU:CSL | $69.66 Billion | AU$202.92 |
Market Capitalization of City Therapeutics, Inc. Common Stock (2026–2026)
Market capitalization of City Therapeutics, Inc. Common Stock from 2026 to today. Between 2026 and today, City Therapeutics, Inc. Common Stock's market cap moved from $911.01 Million to $ 911.01 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $911.01 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 15th, 2026 the market cap of City Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $911.01 Million USD |
| MoneyControl | $911.01 Million USD |
| MarketWatch | $911.01 Million USD |
| marketcap.company | $911.01 Million USD |
| Reuters | $911.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more